- Affirmative Recovery
- Alternative Dispute Resolution
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Childhood Sexual Abuse Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Wealth Planning, Administration, and Disputes
-
August 6, 2020Hollis Salzman Named to Benchmark Litigation's Top 250 Women in Litigation List
-
July 31, 2020Patrick Arenz and Aaron Fahrenkrog named to Benchmark Litigation 40 & Under Hot List
-
July 27, 2020Christine Yun Sauer Shortlisted for Chambers Diversity and Inclusion Awards
-
August 11, 2020Century City Bar Association Distinguished Speaker Series
-
August 12, 13, 19 and 20, 2020Minnesota Association for Justice (MAJ) 38th Annual Meeting and Virtual Convention
-
August 14, 2020Notable Recent & Pending Class Action Cases in the 9th Circuit and SCOTUS
-
August 3, 2020Request for Amici: Tell SCOTUS to Incentivize Original Fictional Characters through Copyright
-
Summer 2020ANDA Approvals
-
Summer 2020ANDA Litigation Settlements
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Purdue's Sleep Aid Patents Are Obvious, Judge Rules
March 30, 2015
Law360, New York (March 30, 2015, 3:01 PM ET) -- A New Jersey federal judge on Friday found that Purdue Pharmaceutical Products LP’s three patents for sleep aid Intermezzo are invalid for obviousness, granting a win to Actavis Elizabeth LLC, Novel Laboratories Inc. and others whom Purdue sued over plans to market their own generic versions of the drug.
All Content © 2003‐2015, Portfolio Media, Inc.
Law360
READ FULL ARTICLE Related Professionals
Related Publications
Summer 2020
ANDA Approvals
GENERICally Speaking Summer 2020
Summer 2020
ANDA Litigation Settlements
GENERICally Speaking Summer 2020
Summer 2020
Generic Launches 505(b)(2)
GENERICally Speaking Summer 2020
July 2020
Hatch-Waxman Patent Litigation Strategies
Jeffrey Alan Hovden - LexisNexis
Summer 2020
New ANDA Cases
GENERICally Speaking Summer 2020
Related News
June 15, 2020
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.